The Enterprise Value as of December 2024 (TTM) for Molecular Partners AG (MOLN) is 107.67M

According to Molecular Partners AG’s latest financial reports and current stock price. The company's current Enterprise Value is 107.67M. This represents a change of 2.96% compared to the average of 3.52M of the last 4 quarters.

Molecular Partners AG (MOLN) Historical Enterprise Value (quarterly & annually)

How has MOLN Enterprise Value performed in the past?

The mean historical Enterprise Value of Molecular Partners AG over the last ten years is 305.52M. The current 107.67M Enterprise Value has changed 3.42% with respect to the historical average. Over the past ten years (40 quarters), MOLN's Enterprise Value was at its highest in in the March 2016 quarter at 835.39M. The Enterprise Value was at its lowest in in the December 2023 quarter at -70218218.32.

Molecular Partners AG (MOLN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Molecular Partners AG Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Molecular Partners AG (MOLN) Average Enterprise Value

How has MOLN Enterprise Value performed in the past?

The current Enterprise Value of Molecular Partners AG (MOLN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Molecular Partners AG (MOLN) Enterprise Value vs. Peers

How is MOLN’s Enterprise Value compared to its peers?

Molecular Partners AG’s Enterprise Value is less than Mineralys Therapeutics, Inc. (502.94M), greater than AN2 Therapeutics, Inc. (8.33M), less than Pharvaris N.V. (678.28M), greater than PepGen Inc. (103.55M), greater than MediciNova, Inc. (61.90M), greater than Anebulo Pharmaceuticals, Inc. (31.01M), less than Champions Oncology, Inc. (116.09M), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than Rezolute, Inc. (248.88M), greater than HCW Biologics Inc. (26.89M), less than Eliem Therapeutics, Inc. (0), greater than PMV Pharmaceuticals, Inc. (42.60M), less than Edgewise Therapeutics, Inc. (2.80B), greater than Rallybio Corporation (12.72M), less than Opthea Limited (552.49M), less than Monte Rosa Therapeutics, Inc. (356.78M), less than Entrada Therapeutics, Inc. (636.62M), greater than Vigil Neuroscience, Inc. (32.87M),

Build a custom stock screener for Molecular Partners AG (MOLN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Molecular Partners AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Molecular Partners AG (MOLN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Molecular Partners AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.